TG Therapeutics, Inc. (TGTX)
Automate Your Wheel Strategy on TGTX
With Tiblio's Option Bot, you can configure your own wheel strategy including TGTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TGTX
- Rev/Share 2.6343
- Book/Share 1.6178
- PB 22.0738
- Debt/Equity 0.0378
- CurrentRatio 4.0229
- ROIC 0.1128
- MktCap 5669141050.0
- FreeCF/Share -0.4165
- PFCF -92.7922
- PE 133.7896
- Debt/Assets 0.0137
- DivYield 0
- ROE 0.1888
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Why TG Therapeutics Stock Was Tumbling Today
Published: May 05, 2025 by: The Motley Fool
Sentiment: Neutral
A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -12.32%) shareholders on Monday.
Read More
TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
TG Therapeutics' Q1 2025 earnings report showed strong revenue growth, with Briumvi net revenues rising to $119.7m, prompting an increase in full-year revenue guidance. Despite a >15% drop in stock value post-earnings, TGTX shares remain up significantly over 6 months, 1 year, and 5 years, reflecting strong market performance. Briumvi competes well against major MS therapies, boasting superior efficacy, less frequent dosing, and a promising subcutaneous version in development.
Read More
TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Michael DiFiore - Evercore ISI Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast.
Read More
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.
Read More
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.
Read More
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
Read More
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Published: March 14, 2025 by: Seeking Alpha
Sentiment: Positive
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy.
Read More
TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Neutral
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald Michael DiFiore - Evercore ISI Ed White - H.C. Wainwright Eric Joseph - JPMorgan Mayank Mamtani - B.
Read More
About TG Therapeutics, Inc. (TGTX)
- IPO Date 2010-05-03
- Website https://www.tgtherapeutics.com
- Industry Biotechnology
- CEO Mr. Michael S. Weiss Esq.
- Employees 352